Bausch Health Companies I... (BHC)
NYSE: BHC
· Real-Time Price · USD
4.71
-0.22 (-4.46%)
At close: May 06, 2025, 1:23 PM
-4.46% (1D)
| Bid | 4.7 |
| Market Cap | 1.74B |
| Revenue (ttm) | 9.6B |
| Net Income (ttm) | -42.62M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -39.21 |
| Forward PE | 1.16 |
| Analyst | Hold |
| Ask | 4.75 |
| Volume | 921,923 |
| Avg. Volume (20D) | 2,487,685 |
| Open | 4.93 |
| Previous Close | 4.93 |
| Day's Range | 4.71 - 5.05 |
| 52-Week Range | 3.96 - 9.85 |
| Beta | 0.43 |
About BHC
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...
Sector Healthcare
IPO Date Mar 29, 1994
Employees 20,700
Stock Exchange NYSE
Ticker Symbol BHC
Website https://www.bauschhealth.com
Analyst Forecast
According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 70.03% from the latest price.
Stock ForecastsEarnings Surprise
Bausch Health Companies has released their quartely earnings
on Apr 30, 2025:
2 weeks ago
+9.96%
Bausch Health shares are trading higher after anno...
Unlock content with
Pro Subscription
2 months ago
+10.29%
Bausch Health shares are trading higher after the company reported better-than-expected Q4 sales.
